Oncology News | pharmaphorum

News

Deal allows UK to rejoin EU's Horizon R&D funding scheme

After years of Brexit-related wrangling, the UK is poised to rejoin the EU's Horizon Europe programme which provides funding for scientific research.

News

Tivdak boosts survival in advanced cervical cancer

Seagen and Genmab's antibody-drug conjugate Tivdak has been shown to improve overall survival when used as a second-line monotherapy for recurrent or metastatic cervical c

News

Roche seeks early-stage lung cancer use for Alecensa

Roche plans to file its Alecensa drug for use in early-stage ALK-positive non-small cell lung cancer (NSCLC), potentially making it the first targeted therapy for these pa

News

AI specialist Intelligent Omics bags J&J deal

UK artificial intelligence (AI) specialist Intelligent Omics has entered into a research collaboration with Johnson & Johnson, within weeks of joining the big pharma's

News

Keytruda gets front-line gastric cancer okay in EU

The European Commission has given approval to MSD's Keytruda as a first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

News

GB first to approve Roche's subcutaneous Tecentriq

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator to approve Roche's subcutaneous (SC) formulation of cancer immunotherapy

Deal allows UK to rejoin EU's Horizon R&D funding scheme

Tivdak boosts survival in advanced cervical cancer

Roche seeks early-stage lung cancer use for Alecensa

AI specialist Intelligent Omics bags J&J deal

Keytruda gets front-line gastric cancer okay in EU

GB first to approve Roche's subcutaneous Tecentriq

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks